KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of GoodwillCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Short-Term Debt repayments (2020 - 2023)

Teva Pharmaceutical Industries' Short-Term Debt repayments history spans 3 years, with the latest figure at $500.0 million for Q4 2023.

  • For the quarter ending Q4 2023, Short-Term Debt repayments changed N/A year-over-year to $500.0 million, compared with a TTM value of $700.0 million through Dec 2024, down 41.67%, and an annual FY2023 reading of $700.0 million, changed N/A over the prior year.
  • Short-Term Debt repayments for Q4 2023 was $500.0 million at Teva Pharmaceutical Industries, up from $200.0 million in the prior quarter.
  • The five-year high for Short-Term Debt repayments was $500.0 million in Q4 2021, with the low at $200.0 million in Q3 2023.
  • Average Short-Term Debt repayments over 3 years is $410.8 million, with a median of $471.5 million recorded in 2020.
  • Biggest YoY gain for Short-Term Debt repayments was 12.87% in 2021; the steepest drop was 12.87% in 2021.
  • Tracing TEVA's Short-Term Debt repayments over 3 years: stood at $443.0 million in 2020, then rose by 12.87% to $500.0 million in 2021, then changed by 0.0% to $500.0 million in 2023.
  • Per Business Quant, the three most recent readings for TEVA's Short-Term Debt repayments are $500.0 million (Q4 2023), $200.0 million (Q3 2023), and $500.0 million (Q4 2021).